ARCHIVES OF CARDIOVASCULAR DISEASE. Patient selection for transcatheter aortic valve implantation: Patient risk profile and anatomical selection criteria

Nicolo Piazza, Ruediger Lange, Giuseppe Martucci, Patrick W. Serruys

Patient selection plays a crucial role in the success of transcatheter aortic valve implantation (TAVI). It requires meticulous attention to the smallest of details and needs to be performed in a systematic manner for every patient. In essence, the patient must be assessed from access to implantation site. Becoming over ‘‘complacent’’ and ‘‘routine’’ may lead to failure and impact patient safety. TAVI is indicated for high or prohibitive surgical risk patients with severe aortic stenosis. Some patients, however, are too high risk even for TAVI. In addition to patient risk evaluation, anatomical selection criteria need to be considered. Multimodality imaging, using a combination of angiography, echocardiography and multislice computed tomography, is necessary to determine the anatomical suitability for the procedure. Archives of Cardiovascular Disease (2012) 105, 165—173. Copyright © 2012 Elsevier Masson SAS. All rights reserved.

ARCHIVES OF CARDIOVASCULAR DISEASE. Transcatheter aortic valve implantation: Surgical perspectives

Thomas Walther, Jörg Kempfert, Friedrich W. Mohr

Aortic valve replacement (AVR) is a routine procedure for decades to treat patients with symptomatic aortic stenosis. The introduction of transcatheter aortic valve implantation (TAVI) by Professor Alain Cribier has paved the way for minimally invasive therapeutic options for elderly and high-risk patients with aortic stenosis. Transfemoral and transapical aortic valve implantations have become routine procedures in many centres around Europe. TAVI is usually being performed together by experienced cardiologists and cardiac surgeons who build the interdisciplinary ‘Heart Team’. In the future, improved devices together with advanced fusion imaging will lead to a further improvement in clinical outcomes for the sake of our patients. Archives of Cardiovascular Disease (2012) 105, 174—180 Copyright © 2012 Published by Elsevier Masson SAS.

ARCHIVES OF CARDIOVASCULAR DISEASE. Transcatheter aortic valve implantation: Our vision of the future

Alec Vahaniana, Dominique Himbert, Éric Brochet, Jean-Pol Depoix, Bernard Iung, Patrick Nataf

Transcatheter aortic valve implantation (TAVI), introduced 10 years ago by Alain Cribier, has now been performed in more than 50,000 patients worldwide. Our vision of the main directions for the future are fourfold. Firstly, the ‘Heart Team’ is and will remain, essential for patient selection and the performance of the procedure. Careful training and controlled diffusion of the technique to medico-surgical centres are also keys to success. Secondly, patient selection must be refined, in order to predict the risk of surgery and that of TAVI. Copyright © 2012 Elsevier Masson SAS. All rights reserved.

INTERNATIONAL JOURNAL STROKE. Prevention of stroke in patients with patent foramen ovale

H. P. Mattle, B. Meier and K. Nedeltchev

Patent foramen ovale is found in 24% of healthy adults and 38% of patients with cryptogenic stroke. This ratio and case reports indicate that patent foramen ovale and stroke are associated, probably because of paradoxical embolism. In healthy people with patent foramen ovale, embolic events are not more frequent than in controls, and therefore no primary prevention is needed. However, once ischaemic events occur, the risk of recurrence is substantial and prevention becomes an issue. Acetylsalicylic acid and warfarin reduce this risk to the same level as in patients without patent foramen ovale. Patent foramen ovale with a coinciding atrial septal aneurysm, spontaneous or large right-to-left shunt, or multiple ischaemic events potentiates the risk of recurrence. Transcatheter device closure has therefore become an intriguing addition to medical treatment, but its therapeutic value still needs to be confirmed by randomised-controlled trials. Copyright 2010 The Authors. Journal compilation. Copyright 2010 World Stroke Organization International Journal of Stroke Vol 5, April 2010, 92–102

NETHERLAND HEART JOURNAL. Percutaneous left atrial appendage closure for stroke prevention in atrial fibrillation

M. J. Swaans & M. C. Post & B. J. W. M. Rensing & L. V. A. Boersma

Percutaneous left atrial appendage (LAA) closure can be an alternative to coumadin treatment in patients with atrial fibrillation (AF) at high risk for thromboembolic events and/or bleeding complications. We report the initial experience with this new technique. Neth Heart J (2012) 20:161–166. Copytight Springer Media / Bohn Stafleu van Loghum 2012

YONSEI MEDICAL JOURNAL. Early Experience Using a Left Atrial Appendage Occlusion Device in Patients with Atrial Fibrillation

Yung Ly Kim, Boyoung Joung, Young Keun On, Chi Young Shim, Moon Hyoung Lee, Young-Hoon Kim, and Hui-Nam Pak

Atrial fibrillation (AF) is one of the major risk factors for ischemic stroke, and 90% of thromboembolisms in these patients arise from the left atrial appendage (LAA). Recently, it has been documented that an LAA occlusion device (OD) is not inferior to warfarin therapy, and that it reduces mortality and risk of stroke in patients with AF. Yonsei Med J 53(1):83-90, 2012. © Copyright: Yonsei University College of Medicine 2012

JACC. The Risk of Thromboembolism and Need for Oral Anticoagulation After Successful Atrial Fibrillation Ablation

Sakis Themistoclakis, MD, Andrea Corrado, MD, Francis E. Marchlinski, MD, Pierre Jais, MD, Erica Zado, PAC, Antonio Rossillo, MD, Luigi Di Biase, MD, Robert A. Schweikert, MD, Walid I. Saliba, MD, Rodney Horton, MD, Prasant Mohanty, MBBS, MPH, Dimpi Patel, DO, David J. Burkhardt, MD, Oussama M. Wazni, MD, Aldo Bonso, MD, David J. Callans, MD, Michel Haissaguerre, MD, Antonio Raviele, MD, Andrea Natale, MD

Journal of the American College of The aim of this multicenter study was to evaluate the safety of discontinuing oral anticoagulation therapy (OAT) after apparently successful pulmonary vein isolation. Cardiology Vol. 55, No. 8, 2010. Copyright © 2010 by the American College of Cardiology Foundation ISSN: 0735-1097/10. Published by Elsevier Inc.

CARDIOVASCULAR DISORDERS. Premature ventricular contractions originating from the left ventricular septum: Results of Radiofrequency Catheter Ablation in twenty patients

Li Jia†, Li Yue-Chun†, Ji Kang-Ting, Zhou Na-Dan, Lin Jia-Xuan, Zhang Wen-Wu, Yang Peng-Lin, Tang Ji-Fei and Lin Jia-Feng

RFCA has been established as an effective and curative therapy for severely symptomatic PVC from the outflow tract in structurally normal hearts. However, it is unknown whether PVCs originating from the left ventricular septum, are effectively eliminated by RFCA. This study aimed to investigate electrophysiologic characteristics and effects of Radiofrequency catheter ablation (RFCA) for patients with symptomatic premature ventricular contraction (PVC) originating from the left ventricular septum without including fascicular PVCs. Jia et al. BMC Cardiovascular Disorders 2011, 11:27 http://www.biomedcentral.com/1471-2261/11/27. Copyright © 2011 Jia et al; licensee BioMed Central Ltd.

CARDIOVASCULAR DISORDERS. Clinical outcomes after treatment of multiple lesions with zotarolimus-eluting versus sirolimuseluting coronary stents (a SORT OUT III substudy)

Troels Thim, Michael Maeng, Jens Flensted Lassen, Anne Kaltoft, Lisette Okkels Jensen, Jan Ravkilde, Per Thayssen, Søren Galatius, Evald Høj Christiansen, Thomas Engstrøm, Morten Madsen, Leif Thuesen and Hans Henrik Tilsted

Data on clinical outcomes among patients treated with the zotarolimus-eluting Endeavor™ stent versus the sirolimus-eluting Cypher™ stent favor the sirolimus-eluting stent. However, a separate comparison of clinical outcome among patients treated for multiple lesions with these stents is lacking. We performed this comparison within the SORT OUT III trial data set. Thim et al. BMC Cardiovascular Disorders 2012, 12:18 http://www.biomedcentral.com/1471-2261/12/18. Copyright © 2012 Thim et al; licensee BioMed Central Ltd.

JACC. Long-Term Outcomes After Transcatheter Aortic Valve Implantation in High-Risk Patients With Severe Aortic Stenosis

Neil E. Moat, MBBS, MS, Peter Ludman, MA, MD, Mark A. de Belder, MA, MD, Ben Bridgewater, PHD, Andrew D. Cunningham, PHD, Christopher P. Young, MD, Martyn Thomas, MD, Jan Kovac, MD, Tom Spyt, MD, Philip A. MacCarthy, BS, PHD, Olaf Wendler, MD, PHD, David Hildick-Smith, MD, Simon W. Davies, MBBS, MD, Uday Trivedi, MBBS, Daniel J. Blackman, MD, Richard D. Levy, MD, Stephen J. D. Brecker, MD, Andreas Baumbach, MD, Tim Daniel, MB, CHB, Huon Gray, MD, Michael J. Mullen, MBBS, MD

The objective was to define the characteristics of a real-world patient population treated with transcatheter aortic valve implantation (TAVI), regardless of technology or access route, and to evaluate their clinical outcome over the mid to long term. Journal of the American College of Cardiology Vol. 58, No. 20, 2011. Copyright © 2011 by the American College of Cardiology Foundation ISSN 0735-1097. Published by Elsevier Inc.

JOURNAL OF INTERVENTIONAL CARDIOLOGY. Long-Term Safety and Effectiveness of Drug-Eluting Stents Compared to Bare Metal Stents following Successful PCI in Non-ST-Elevation Myocardial Infarction: GHOST Registry

KISHORE J. HARJAI, M.D., F.A.C.C., SUDHAKAR SATTUR, M.D., PAMELA ORSHAW, R.N., and JUDY BOURA, M.S. From the Guthrie Clinic, Sayre, Pennsylvania

The long-term safety and effectiveness of drug-eluting stents (DES) versus bare metal stents (BMS) in non-ST-segment elevation myocardial infarction (NSTEMI) beyond 2 years after percutaneous coronary intervention (PCI) is unknown. Journal of Interventional Cardiology. Vol. 25, No. 1, 2012. Copyright 2011, Wiley Periodicals, Inc.

CLINICAL CARDIOLOGY. Safety of Dental Extractions in Coronary Drug-Eluting Stenting Patients Without Stopping Multiple Antiplatelet Agents

Mahn-Won Park, MD; Sung-Ho Her, MD; Jong Bum Kwon, MD; Jae Beom Lee, MD; Min-Seok Choi, MD; Jung Sun Cho, MD; Dong-Bin Kim, MD; Wook-Sung Chung, MD; Ki-Bae Seung, MD; Keon-Yeop Kim, MD

The risk of excessive bleeding prompts physicians to stop multiple antiplatelet agents before minor surgery, which puts coronary stenting patients at risk for adverse thrombotic events. Hypothesis: We hypothesized that most dental extractions can be carried out safely without stopping multiple antiplatelet agents. Clin. Cardiol. 35, 4, 225–230 (2012) 225 Published online in Wiley Online Library. Copyright © 2012 Wiley Periodicals, Inc.

JACC: CARDIOVASCULAR INTERVENTIONS. Predictors for New-Onset Complete Heart Block After Transcatheter Aortic Valve Implantation

Sabine Bleiziffer, MD, Hendrik Ruge, MD, Jürgen Hörer, MD, Andrea Hutter, MD, Sarah Geisbüsch, MD, Gernot Brockmann, MD, Domenico Mazzitelli, MD, Robert Bauernschmitt, MD, PhD, Rüdiger Lange, MD, PhD

The aim of this study was to identify risk factors for new-onset atrioventricular (AV) block requiring pacemaker (PM) implantation after transcatheter aortic valve implantation (TAVI). Copyright © 2010 BY THE AMERICAN COLEGE OF CARDIOLOGY FOUNDATION ISSN 1936-8798. PUBLISHED BY ELSEVIER INC.

CIRCULATION: CARDIOVASCULAR INTERVENTIONS. Intravascular Ultrasound Results From the NEVO ResElution-I Trial : Comparison of Sirolimus-Eluting NEVO Stents With Paclitaxel-Eluting Taxus Liberté Stents in De Novo Native Coronary Artery Lesions

Hiromasa Otake, MD; Yasuhiro Honda, MD; Brian K. Courtney, MD, MSEE; Takao Shimohama, MD; Junya Ako, MD; Katsuhisa Waseda, MD; Nathalie Macours, PhD; Campbell Rogers, MD; Jeffrey J. Popma, MD, PhD; Alexandre Abizaid, MD, PhD; John A. Ormiston, MBChB; Christian Spaulding, MD, PhD; Sidney A. Cohen, MD, PhD; Peter J. Fitzgerald, MD, PhD

Background—The NEVO sirolimus-eluting stent (NEVO SES) is a novel cobalt-chromium stent combining sirolimus release from reservoirs with bioabsorbable polymer to reduce spatial and temporal polymer exposure. The aim of this study was to assess the arterial response to the NEVO SES in a randomized, blinded comparison versus the surface-coated TAXUS Liberte paclitaxel-eluting stent (TAXUS Liberte´ PES) in human native coronary lesions using intravascular ultrasound (IVUS). Copyright © 2011 American Heart Association. All rights reserved. Print ISSN: 1941-7640. Online ISSN: 1941-7632

CIRCULATION: CARDIOVASCULAR INTERVENTIONS. Technical Challenge of Transfemoral Aortic Valve Implantation in a Patient With Severe Aortic Regurgitation

Ulrike Krumsdorf, Markus Haass, Marcus Pirot, Emmanuel Chorianopoulos, Hugo A. Katus and Raffi Bekeredjian

Transfemoral aortic valve implantation (TAVI) has become an important interventional technique for patients with severe aortic stenosis (AS) and very high surgical risks. Several studies have demonstrated the feasibility and clinical success of TAVI procedures. Copyright © 2011 American Heart Association. All rights reserved. Print ISSN: 1941-7640. Online ISSN: 1941-7632.